JP2022552329A5 - - Google Patents
Info
- Publication number
- JP2022552329A5 JP2022552329A5 JP2022522343A JP2022522343A JP2022552329A5 JP 2022552329 A5 JP2022552329 A5 JP 2022552329A5 JP 2022522343 A JP2022522343 A JP 2022522343A JP 2022522343 A JP2022522343 A JP 2022522343A JP 2022552329 A5 JP2022552329 A5 JP 2022552329A5
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- water
- ray powder
- cancer
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106308A JP2025143319A (ja) | 2019-10-14 | 2025-06-24 | 化合物の塩及びその結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910973785 | 2019-10-14 | ||
| CN201910973785.3 | 2019-10-14 | ||
| PCT/CN2020/120594 WO2021073494A1 (en) | 2019-10-14 | 2020-10-13 | The salts of a compound and the crystalline forms thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106308A Division JP2025143319A (ja) | 2019-10-14 | 2025-06-24 | 化合物の塩及びその結晶形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552329A JP2022552329A (ja) | 2022-12-15 |
| JP2022552329A5 true JP2022552329A5 (https=) | 2023-10-17 |
Family
ID=75537486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522343A Pending JP2022552329A (ja) | 2019-10-14 | 2020-10-13 | 化合物の塩及びその結晶形態 |
| JP2025106308A Pending JP2025143319A (ja) | 2019-10-14 | 2025-06-24 | 化合物の塩及びその結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106308A Pending JP2025143319A (ja) | 2019-10-14 | 2025-06-24 | 化合物の塩及びその結晶形態 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12559472B2 (https=) |
| EP (1) | EP4045484A4 (https=) |
| JP (2) | JP2022552329A (https=) |
| KR (1) | KR20220088712A (https=) |
| CN (3) | CN119751422A (https=) |
| AR (1) | AR120202A1 (https=) |
| AU (1) | AU2020367905A1 (https=) |
| BR (1) | BR112022007035A2 (https=) |
| CA (1) | CA3154064A1 (https=) |
| IL (1) | IL292206B2 (https=) |
| MX (1) | MX2022004274A (https=) |
| TW (1) | TWI895290B (https=) |
| UA (1) | UA129777C2 (https=) |
| WO (1) | WO2021073494A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7736357B2 (ja) * | 2021-12-13 | 2025-09-09 | アビスコ セラピューティクス カンパニー リミテッド | Ｆｇｆｒ４阻害剤酸性塩およびその製造方法と使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| WO2014139145A1 (en) * | 2013-03-15 | 2014-09-18 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| KR102548229B1 (ko) * | 2015-04-14 | 2023-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 결정질 fgfr4 억제제 화합물 및 그의 용도 |
| WO2018099451A1 (zh) | 2016-12-01 | 2018-06-07 | 和记黄埔医药（上海）有限公司 | 化合物的晶型 |
-
2020
- 2020-10-13 BR BR112022007035A patent/BR112022007035A2/pt unknown
- 2020-10-13 CN CN202411784884.4A patent/CN119751422A/zh active Pending
- 2020-10-13 WO PCT/CN2020/120594 patent/WO2021073494A1/en not_active Ceased
- 2020-10-13 UA UAA202201538A patent/UA129777C2/uk unknown
- 2020-10-13 KR KR1020227014838A patent/KR20220088712A/ko active Pending
- 2020-10-13 JP JP2022522343A patent/JP2022552329A/ja active Pending
- 2020-10-13 EP EP20876200.5A patent/EP4045484A4/en active Pending
- 2020-10-13 CN CN202411778340.7A patent/CN119462616A/zh active Pending
- 2020-10-13 AU AU2020367905A patent/AU2020367905A1/en active Pending
- 2020-10-13 IL IL292206A patent/IL292206B2/en unknown
- 2020-10-13 CA CA3154064A patent/CA3154064A1/en active Pending
- 2020-10-13 US US17/768,951 patent/US12559472B2/en active Active
- 2020-10-13 CN CN202080071856.1A patent/CN114555558B/zh active Active
- 2020-10-13 MX MX2022004274A patent/MX2022004274A/es unknown
- 2020-10-13 TW TW109135330A patent/TWI895290B/zh active
- 2020-10-13 AR ARP200102815A patent/AR120202A1/es unknown
-
2025
- 2025-06-24 JP JP2025106308A patent/JP2025143319A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102272124B (zh) | 舒尼替尼苹果酸盐的新晶形 | |
| TWI597277B (zh) | 一種酪胺酸激酶抑制劑的二馬來酸鹽的第ｉ型結晶及製備方法 | |
| US20090192200A1 (en) | Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof | |
| CN103923001B (zh) | 瑞戈非尼盐及其晶型、制备方法 | |
| RS60563B1 (sr) | Postupak za dobijanje dimaleatne soli amino krotonilnih jedinjenja | |
| JP2011512396A (ja) | 新規な多形およびその調製方法 | |
| KR102266680B1 (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
| JP2011515421A5 (https=) | ||
| CN102070618A (zh) | 一种化合物及其晶体 | |
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| CN102964384B (zh) | 阿德福韦酯没食子酸共晶及其制备方法和组合物 | |
| WO2009117899A1 (zh) | 4-苯胺喹唑啉衍生物多晶型物及其制法和应用 | |
| JP2022552329A5 (https=) | ||
| CN102093307A (zh) | 法莫替丁共晶 | |
| IL292206B1 (en) | The salts of a compound and the crystalline forms thereof | |
| CN110372635B (zh) | 氢溴酸沃替西汀α晶型的制备方法 | |
| CN103450133A (zh) | 具有抗肿瘤活性的东莨菪素衍生物、其制备方法及用途 | |
| TW201815768A (zh) | 氘代咪唑二酮類化合物的製備方法 | |
| CN105859691A (zh) | 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法 | |
| US20110263670A1 (en) | Novel polymorphs of sunitinib and processes for their preparation | |
| CN112225730B (zh) | 一种稠环化合物的晶型、其组合物、制备方法及其应用 | |
| CN105849093A (zh) | 卡巴他赛无水结晶形式、其制备方法和药用组合物 | |
| WO2019037591A1 (zh) | 盐酸美法仑晶型及其制备方法与应用 | |
| CN101353343A (zh) | 高纯度盐酸诺拉曲塞二水合物的制备方法 | |
| CN111995571A (zh) | 一种瑞戈非尼与马来酸的共晶及其制备方法 |